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Abstract  56 
 57 
Objective: Sclerostin (SOST) has been identified as an important regulator of bone 58 
formation, however, it has not been previously implicated in arterial disease. The aim of this 59 
study was to assess the role of SOST in aortic aneurysm (AA) and atherosclerosis using 60 
human samples, a mouse model and in vitro investigations.  61 
 62 
Approach and Results: SOST protein was down regulated in human and mouse AA 63 
samples compared to controls. Transgenic introduction of human SOST in ApoE-/- mice 64 
(SOSTTg.ApoE-/-) and administration of recombinant mouse Sost (rmSost) inhibited 65 
angiotensin II-induced AA and atherosclerosis. Serum concentrations of a number of pro-66 
inflammatory cytokines were significantly reduced in SOSTTg.ApoE-/- mice. Compared to 67 
controls, the aortas of mice receiving rmSost and SOSTTg.ApoE-/- mice showed reduced 68 
matrix degradation, reduced elastin breaks and preserved collagen. Decreased inflammatory 69 
cell infiltration and a reduction in the expression of Wnt/β-catenin responsive genes including 70 
matrix metalloprotenase-9, osteoprotegerin, and osteopontin were observed in the aortas of 71 
SOSTTg.ApoE-/- mice. SOST expression was downregulated and the Wnt/β-catenin pathway 72 
was activated in human AA samples. The CpG islands in the SOST gene promoter showed 73 
significantly higher methylation in human AA samples compared to controls. Incubation of 74 
vascular smooth muscle cells with the de-methylating agent 5-azacytidine resulted in 75 
upregulation of SOST suggesting that SOST is epigenetically regulated.  76 
 77 
Conclusion: This study identifies for the first time that SOST is expressed in the aorta and 78 
downregulated in human AA possibly due to epigenetic silencing. Upregulating SOST 79 
inhibits AA and atherosclerosis development with potential important implications for treating 80 
these vascular diseases. 81 
 82 
Key Words: Aortic aneurysm, atherosclerosis, apolipoprotein E-null mouse, Sclerostin, DNA 83 
methylation, epigenetics. 84 
 85 
 86 
Nonstandard Abbreviations and Acronyms 
AA Aortic aneurysm 
AngII Angiotensin II 
ApoE  Apolipoprotein E  
CpG Cytosine-phosphate-Guanine 
SOST Sclerostin (gene = SOST) 
MMP  Metalloproteinase (gene = Mmp) 
OPG Osteoprotegerin 
OPN Osteopontin 
5-Aza 5-Azacytidine 
SRA Suprarenal aorta 
VSMC Vascular smooth muscle cell 
Wnt Wingless-type mouse mammary virus integration site 
87 
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Introduction 88 
 89 
Aortic aneurysm (AA) and atherosclerosis are important causes of morbidity and mortality. 90 
Older age and smoking are important risk factors for cardiovascular disease and one of the 91 
mechanisms by which they may promote vascular disease may be via stimulating epigenetic 92 
changes [1-3]. While improvements have been made in the management of cardiovascular 93 
disease there is a need to develop novel therapies to advance patient management [2, 3].  94 
 95 
Sclerostin (SOST) is a secreted cysteine-knot protein expressed in bone where it has been 96 
shown to control bone mineralization [4, 5]. SOST has no known function within human 97 
arteries however a recent study identified its expression within the aorta suggesting it may 98 
have a role in aortic diseases [6]. One of the major regulatory roles of SOST is inhibition of 99 
the canonical Wingless-type mouse mammary virus integration site (Wnt) signalling pathway 100 
by binding to the transmembrane Wnt co-receptor low-density lipoprotein receptor-related 101 
proteins (LRP)-4, 5 and 6 [7-9]. A number of studies have demonstrated a significant role for 102 
the Wnt signalling pathway in vascular development and remodelling [10, 11]. Traditionally, 103 
the canonical Wnt signalling pathway is activated when Wnt binds to its heterodimeric 104 
receptor complex [constituted by frizzled (Fz) family proteins and LRP-5/6 co-receptor] 105 
located at the cell membrane, leading to a reduction of β-catenin degradation, increased 106 
translocation of β-catenin into the nucleus and subsequent activation of Wnt target genes 107 
[12, 13]. Wnt/β-catenin signalling controls the expression of osteoprotegerin (OPG), 108 
osteopontin (OPN) and matrix metalloproteinase (MMP) -2, -7 and -9 which have all been 109 
implicated in aortic disease [14-16].  110 
 111 
We hypothesised that SOST was differentially expressed in AA and played an important role 112 
in AA pathogenesis via regulation of the Wnt/β-catenin signalling pathway. We investigated 113 
this using human AA samples and an experimental model. 114 
 115 
Materials and Methods 116 
 117 
Materials and Methods are available in the online-only data supplement.  118 
 119 
Results 120 
 121 
Sost was downregulated in the aortas of apolipoprotein E (ApoE-/-) mice that 122 
developed AA  123 
Angiotensin II (AngII) infusion for 28 days in ApoE-/- mice results in AA formation, however 124 
we and others have reported that this phenotype is not fully penetrant and a small subset of 125 
these mice do not develop AA following AngII infusion [17]. Protein levels of Sost were 126 
analysed in extracts of suprarenal aortas (SRA) from ApoE-/- mice that received AngII for 28 127 
days. We analysed two groups of mice. Firstly, mice that developed marked SRA dilatation 128 
following AngII infusion (Median SRA diameter 2.57 mm, IQR 2.34-2.81; n=5) and secondly 129 
mice that developed minimal SRA dilatation following AngII infusion (Median SRA diameter 130 
1.06 mm, IQR 0.88-1.11; n=6). The SRA diameters of the second group were similar to mice 131 
that received saline infusion alone, as we have previously reported [17]. Sost protein was 132 
detected within the mouse aorta and its expression levels were significantly reduced by ~3-133 
fold (P=0.004) in aortas of mice that developed marked SRA dilatation compared to aortas 134 
from mice that did not develop marked SRA dilatation after AngII infusion (Figure 1. A). 135 
These observations suggested a negative correlation between Sost levels and AA formation 136 
and highlighted the relevance of the AngII-induced mouse model to further investigate the 137 
role of SOST in AA formation. 138 
 139 
SOST overexpression protected ApoE-/- mice from AA formation 140 
Given the significant reduction in aortic SOST expression observed in mouse AAs, we 141 
sought to determine whether SOST played a protective role against AA development using 142 
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two approaches: (a) transgenic introduction of human SOST in ApoE-/- mice (SOSTTg.ApoE-/-143 
) and (b) intra-peritoneal injections of recombinant mouse Sost (rmSost) protein in ApoE-/- 144 
mice. SOSTTg.ApoE-/- mice were generated by cross breeding of the B6.SOSTTg mice with 145 
ApoE-/- mice. B6.SOSTTg mice have been previously shown to consistently express high 146 
level of human SOST within the adult heart [18]. In a preliminary experiment, we isolated the 147 
aortas of SOSTTg.ApoE-/- (n=5) and ApoE-/- mice (n=5) and compared the levels of Sost 148 
expression in protein extracts by Western blotting. We observed a significant higher median 149 
Sost protein expression in the aortas of SOSTTg.ApoE-/- (1.41 AU, IQR 1.27-1.42) compared 150 
to control mice (1.06 AU, IQR 0.95-1.22, P = 0.037) (Figure 1. B).  151 
 152 
We measured the diameters of the SRA and infrarenal aorta (IRA) of 12 week old 153 
SOSTTg.ApoE-/- (n=6) and ApoE-/- (n=6) mice using ultrasound and found these to be similar 154 
(Supplementary Table 1). AngII infusion is a well-established method for the induction of AA 155 
and aortic rupture in mice [19]. AngII was subcutaneously infused into ApoE-/- (n=12) and 156 
SOSTTg.ApoE-/- (n=12) mice. In the control (ApoE-/-) group there were 4 deaths due to 157 
rupture of the aortic arch (rupture rate 33%) within the first week of starting the AngII 158 
infusion, however there were no aortic ruptures in the mice carrying the human SOST 159 
transgene (P=0.028) (Supplementary Table 2). Aortas were harvested at day 28, and ex vivo 160 
diameters of the aortic arch, thoracic aorta, SRA and IRA were measured. Mean (± S.E.M.) 161 
maximum SRA diameter was significantly smaller in SOSTTg.ApoE-/- (1.42±0.12 mm) 162 
compared to control ApoE-/-mice (2.23±0.30 mm, P=0.021) (Figure 2A). Mean diameters of 163 
the aortic arch, thoracic and IRA segments were also smaller in SOSTTg.ApoE-/- mice 164 
(Supplementary Table 3).  165 
 166 
In a further experiment, AngII was infused subcutaneously for 28 days in ApoE-/- mice (n=20) 167 
receiving vehicle control or daily rmSost protein injections (n=20). Three mice died due to 168 
aortic rupture in the rmSost injected group (rupture rate 15%) and 5 mice died of aortic 169 
rupture in the saline injected group (rupture rate 25%). All the ruptures occurred within the 170 
aortic arch (Supplementary Table 2). The mean maximum SRA diameter of the rmSost 171 
injected group (1.44±0.12 mm) was significantly smaller than that of the vehicle control 172 
group (2.06±1.44 mm, P=0.004) (Figure 2B). Mean diameters of the aortic arch, thoracic 173 
and IRA segments were also smaller in mice receiving rmSost (Supplementary Table 3). 174 
These results supported our hypothesis that SOST plays a protective role against AA 175 
formation in this model. 176 
 177 
SOST protects AngII-infused ApoE-/- mice from atherosclerosis and inflammation 178 
Atherosclerosis and inflammation are consistently observed in patients that have an AA [20]. 179 
AngII infusion stimulates the progression of atherosclerosis in ApoE-/- mice [19, 21]. 180 
Therefore, we assessed the possible protective role of SOST on atherosclerosis progression 181 
by examining intimal plaque formation in the aortic arch and systemic inflammation levels in 182 
plasma collected at 28 days after starting AngII infusion. Marked atherosclerotic plaques 183 
were observed in the aortic arch in ApoE-/- mice after AngII infusion as revealed by en face 184 
Sudan IV staining. Median aortic arch Sudan IV staining areas were significantly smaller in 185 
SOSTTg.ApoE-/- (4.87%, IQR 2.50-9.36, P=0.002; n=6) and ApoE-/- mice injected with rmSost 186 
(6.62%, IQR 5.40-11.06, P=0.008; n=6) compared to the ApoE-/- mice receiving AngII alone 187 
(22.96%, IQR 20.24-39.21, P=0.002; n=6) (Figure 2 C).  188 
 189 
Systemic inflammation was assessed by a cytometric bead assay to evaluate the 190 
concentrations of six inflammatory markers previously implicated in atherosclerosis and AA 191 
formation [22]. In comparison to ApoE-/- mice, SOSTTg.ApoE-/- mice had a significantly lower 192 
mean plasma concentrations of MCP-1 (P=0.003), IL-6 (P=0.001) and TNF-α (P=0.041) after 193 
28 days of AngII infusion (Table 1). Mean concentrations of IL-10 (P=0.079), IFN-γ 194 
(P=0.092), and IL-12 (P=0.060) were non-significantly lower in SOSTTg.ApoE-/- mice (Table 195 
1). The plasma of ApoE-/- mice receiving rmSost injections showed a similar lower 196 
concentration of all inflammatory cytokines assessed in comparison to control mice, however 197 
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the differences did not reach statistical significance (Table 1).  The mean plasma 198 
concentrations of total and active TGF-β1 were similar in control mice to those within 199 
SOSTTg.ApoE-/- mice and ApoE-/- mice receiving rmSost injections (Table 1). These results 200 
suggest that SOST not only suppresses aortic dilatation but also systemic inflammation and 201 
atherosclerosis progression in AngII infused ApoE-/- mice.  202 
 203 
SOST protected AngII-infused ApoE-/- mice from aortic matrix degradation 204 
Extracellular matrix (ECM) remodelling, inflammation and vascular smooth muscle cell 205 
(VSMC) loss are key characteristics of AA [23, 24]. We therefore examined the role of SOST 206 
in protecting against aortic ECM degradation. As expected, hematoxylin and eosin (H&E) 207 
staining showed marked thickening of the aortic wall with extensive matrix remodelling and 208 
degradation in AngII infused ApoE-/- mice (Figure 3A, i). AngII infused ApoE-/- mice also 209 
showed large SRA lumen diameters consistent with the morphometry findings discussed 210 
above. SOSTTg.ApoE-/- (Figure 3B, ii) and ApoE-/- mice administered rmSost exhibited less 211 
lamellar fragmentation, decreased medial inflammation, decreased adventitial atrophy and 212 
comparatively normal SRA lumen diameters compared to ApoE-/- control mice as assessed 213 
by histology (Figure 3A, B).  214 
 215 
To further characterize elastin integrity, we performed elastin Verhoeff-van Gieson (EVG) 216 
staining of SRA sections. EVG staining demonstrated extensive elastin degradation within 217 
the SRA of AngII infused ApoE-/- mice, compared to intact elastin found in both 218 
SOSTTg.ApoE-/-and ApoE-/- mice receiving rmSost (Figure 3C, i-iii). Semi-quantitative 219 
measurements of elastin degradation showed significantly reduced elastin degradation in 220 
SOSTTg.ApoE-/- mice (median grade 2, IQR 1-2, P=0.031) and a similar but non-significant 221 
reduction in ApoE-/- mice receiving rmSost (median grade 1.50, IQR 1-3.25, P=0.140) 222 
compared to ApoE-/- control mice (median grade 3, IQR 2.50-4; Figure 3 E).  223 
 224 
Assessment of picrosirius red staining for collagen within the SRA tissue by polarization 225 
microscopy was performed to further assess collagen distribution in AngII induced AA. 226 
Under polarised light, disrupted collagen distribution and orientation was found within 227 
picrosirius stained SRA sections from ApoE-/- after 28 days of AngII infusion (Figure 3D, i-228 
iii). Picrosirius staining with dark field illumination analysis confirmed low mural collagen 229 
accumulation and localized birefringence within the adventitial layers of SRA sections 230 
obtained from AngII-infused ApoE-/- mice. The overall percentage of picrosirius staining area 231 
was significantly lower in control ApoE-/- (median picrosirius red staining area 4.55%, IQR 232 
1.81-11.37) compared to SOSTTg.ApoE-/-  (median picrosirius red staining area 17.09%, IQR 233 
12.64-18.76, P=0.030) and mice receiving rmSost (median picrosirius red staining area 234 
11.32%, IQR 5.13-17.64, P=0.177) after 28 days of AngII infusion (Figure 3 F).  235 
 236 
SOST protected AngII-infused ApoE-/- mice from macrophage infiltration  237 
Localization of macrophages by immunohistochemistry (IHC) showed a significantly higher 238 
staining area for macrophages within SRA sections of control ApoE-/- (median MOMA-2 239 
staining area 31.12%, IQR 23.92-36.08) compared to both SOSTTg.ApoE-/- (median MOMA-2 240 
staining area 1.40%, IQR 0.00-4.13, P=0.002) and mice receiving rmSost (median MOMA-2 241 
staining area 6.27%, IQR 2.51-15.89, P=0.004) after 28 days of AngII infusion (Figure 4 A, 242 
i-vi, B).  243 
 244 
SOST overexpression is associated with reduced aortic expression of genes 245 
implicated in AA 246 
Matrix degradation and calcification are important pathological changes commonly observed 247 
in end- stage human AA tissues. A number of genes which control these pathological 248 
processes such as MMP-9, OPN (Spp1) and OPG (Tnfrsf11b), have been reported to be 249 
differentially regulated by the Wnt pathway [25-28]. We assessed the relative gene 250 
expression of Mmp-9, Spp1 and Tnfrsf11b in SRA samples obtained from mice infused with 251 
AngII for 28 days. Quantitative RT-PCR showed that the median relative mRNA levels of 252 
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Mmp-9, Tnfrsf11b, and Spp1 were significantly decreased in SOSTTg.ApoE-/- and in rmSost 253 
receiving mice compared to ApoE-/- controls (Table 2). The median relative expression of 254 
Mmp-9 was significantly lower in SOSTTg.ApoE-/- (P=0.002) and rmSost injected (P=0.041) 255 
mice compared to control ApoE-/- mice (Table 2). The median relative gene expression of 256 
Spp1 was significantly lower within SRA samples of SOSTTg.ApoE-/- (P=0.030) and rmSost 257 
injected (P=0.041) mice compared to control ApoE-/- mice (Table 2). Median relative 258 
expression of Tnfrsf11b was also lower in SOSTTg.ApoE-/- (P=0.030) and rmSost injected (P 259 
=0.420) mice compared to control ApoE-/- mice (Table 2).  260 
 261 
The Wnt/β-catenin signalling pathway is activated in AngII-induced AA  262 
SOST is an inhibitory molecule of the Wnt/β-catenin signalling pathway [7], therefore we 263 
examined the expression of the major signalling molecule of the Wnt pathway in mice SRA 264 
samples. The Wnt signalling pathway is regulated by glycogen synthase kinase (GSK)-3β 265 
activity [24]. Non-phosphorylated GSK-3β phosphorylates β-catenin, leading to its 266 
degradation and inhibition of Wnt signalling. Phosphorylation of Gsk-3 β leads to stabilisation 267 
of β-catenin and activation of the Wnt pathway. We observed a ~2 fold higher phospho-268 
GSK-3β: total GSK-3β ratio in SRA samples from mice that developed AA (Median 0.77 AU, 269 
IQR 0.41-1.14; n=4) compared to those that did not develop AA after AngII infusion (Median 270 
0.26, IQR 0.22-0.33, P=0.009; n=6), suggesting that Wnt signalling was activated in AngII 271 
induced AA (Figure 4 C, i, ii).  272 
 273 
We assessed GSK-3β activity (expressed as phosphor-GSK-3β: total GSK-3β ratio) in SRA 274 
samples from ApoE-/- control and SOSTTg.ApoE-/- mice that were infused with AngII for 28 275 
days. Aortic phosphor-GSK-3β: total GSK-3β ratio was significantly lower in SOSTTg.ApoE-/- 276 
(Median 0.91 AU, IQR 0.70-1.30; n=6) when compared to ApoE-/- control mice (Median 1.71 277 
AU, IQR 1.12-2.33, P=0.041; n=6), suggesting suppressed Wnt signalling in SOSTTg.ApoE-/- 278 
mice (Figure 4 D, i, ii). Furthermore, the median relative gene expression of β-catenin 279 
(Ctnn1) was reduced in SRA samples of SOSTTg.ApoE-/- (P=0.035; n=6) and ApoE-/- mice 280 
receiving rmSost (9P=0.073; n=6 each group) compared to ApoE-/- controls (Table 2). 281 
 282 
It has been suggested that GSK-3β is also a substrate for the Akt signalling pathway [29]. 283 
Western blotting analysis revealed that Akt activity (expressed as phospho-Akt: total Akt 284 
ratio) was not different in SRA samples from ApoE-/- control and SOSTTg.ApoE-/- mice after 285 
28 days of Ang-II infusion (Median 1.38 AU, IQR 1.30-1.54 vs Median 1.35 AU, IQR 1.26-286 
1.47; P=0.412; n=5/group) (Figure 4 E, i, ii). This result suggests that Akt signalling was not 287 
relevant to the ability of SOST to limit AA.  288 
 289 
SOST is downregulated and the Wnt/β-catenin signalling pathway is activated in 290 
human AA 291 
We examined the levels of SOST protein expression in biopsies of human AA and those 292 
from normal abdominal aortas of organ donors. Western blotting analysis revealed that 293 
SOST protein expression was significantly lower in the AA tissues (n=6) relative to control 294 
samples from organ donor tissues (P=0.008; n=6). Median protein levels of SOST relative to 295 
β-actin were 0.70 AU (IQR 0.32-1.36) and 0.19 AU (IQR 1.34-0.29) in control organ donor 296 
tissues and AA samples respectively (Figure 5 A, i, ii). 297 
 298 
A similar decrease in SOST protein staining was also observed by IHC in the AA body 299 
biopsies (n=6) compared to the relative normal AA neck biopsies (n=6). IHC of cryostat 300 
sections demonstrated the presence of VSMCs expressing SOST within the AA neck 301 
biopsies. Dense accumulation of SOST expressing cells was observed within the media and 302 
the adventitia within all AA neck biopsies assessed (Figure 5 B, i). In contrast, relatively 303 
sparse presence of SOST expressing cells was observed within media or adventitia of AA 304 
body biopsies (Figure 5 B, ii). Analysis of median relative SOST mRNA expression in AA 305 
body tissue (0.29, IQR 0.21-2.84; n=8) showed a non-significant decrease compared to AA 306 
neck biopsies (1.24, IQR 0.37-4.58, P=0.494; n=8). We also examined the median relative 307 
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expression of β-catenin (CTNNB1) mRNA in the AA body and neck biopsies. A significantly 308 
increased median relative expression of the CTNNB1 gene (1.31, IQR 1.06-1.64; n=8) was 309 
found in the AA body compared to AA neck biopsies (0.97, IQR 0.86-1.26, P=0.049; n=8) 310 
(Figure 5 C).  311 
 312 
SOST is epigenetically silenced in human AA 313 
SOST gene expression has previously been shown to be linked to the average levels of 314 
DNA methylation across the CpG islands located in its proximal promoter [30, 31]. Hence we 315 
assessed the levels of CpG island methylation in the promoter region of SOST in human 316 
aortic DNA samples. The SOST promoter region which was assessed included 17 CpG sites 317 
of which 5 did not pass the quality assessment (Figure 6 A, i - iii). The methylation data 318 
obtained from the remaining 12 sites were used for subsequent analyses. We identified that 319 
the AA samples analysed showed hypermethylation of all CpG sites analysed with an overall 320 
higher percentage of methylation in AA (mean ± S.E.M.= 79.23% ± 2.34; n=32) relative to 321 
control biopsies (mean ± S.E.M.= 61.33% ± 1.39; P< 0.0001; n=32) suggesting that in AA 322 
SOST is epigenetically silenced (Figure 6 B). 323 
 324 
Epigenetically silenced SOST in human VSMC can be reactivated  325 
To investigate the role of DNA methylation in transcriptional silencing of the SOST gene 326 
promoter, we examined the effect of DNA methyl transferase inhibitor (DNMTi) 5-Azacytidine 327 
(5-Aza), on SOST gene expression in VSMCs. Incubation of VSMCs with AA-thrombus-328 
conditioned medium for 24 h resulted in downregulation of SOST gene expression. 329 
Increased transcription of SOST gene (relative mRNA levels) was observed in VSMCs 330 
following 48 h of incubation with 5-Aza (Figure 6 C). Human aortic VSMCs treated for 48 h 331 
with 5-Aza, showed significant upregulation of median relative SOST mRNA expression 332 
(2.21, IQR 1.84-3.74) compared to vehicle controls (1.07, IQR 0.78-1.35, P=0.004) or 333 
VSMCs incubated with AA-thrombus-conditioned media (0.63, IQR 0.25-0.69, P=0.026, 334 
Figure 6 C, i). An opposite effect was observed in the case of relative CTNNB1 expression. 335 
The VSMCs treated for 48 h with 5-Aza, showed downregulation of median relative CTNNB1 336 
mRNA expression (0.43, IQR 0.20-0.56) compared to vehicle controls (0.51, IQR 0.33-0.64, 337 
P=0.041) or VSMCs incubated with AA-thrombus-conditioned media (0.90, IQR 0.66-0.93, 338 
P=0.026, Figure 6 C, ii). 339 
 340 
Discussion 341 
 342 
SOST is a potent inhibitor of bone mineralization but little is known about its role in the 343 
vasculature [32]. In this study we provide evidence for the first time that SOST protects the 344 
aorta from AA and atherosclerosis and that epigenetic silencing of SOST may promote aortic 345 
diseases.  346 
 347 
SOST is known to be an important inhibitor of the Wnt/β-catenin pathway and we provide 348 
evidence that this pathway is upregulated in mouse and human AA. The Wnt/β-catenin 349 
pathway has previously been reported to control the expression of the bone proteins OPG 350 
and OPN [25, 26]. OPN is a secreted highly phosphorylated sialoprotein which is a 351 
prominent component of the mineralized ECM and we previously reported an association 352 
between high serum concentrations of OPN and AA [33]. OPN promotes inflammation [34] 353 
and is also involved in the activation of proteolytic pathways including an increase in pro-354 
MMP-9 activity [35]. OPN deficiency limits AA development in the AngII mouse model [36]. 355 
OPG is a secreted glycoprotein member of the tumor necrosis factor receptor (TNFR) 356 
superfamily [37] and is expressed by a variety of cell types including VSMCs, endothelial 357 
cells, dendritic cells and lymphocytes [38, 39]. OPG concentration within the aortic wall is 358 
positively associated with established markers of AA severity and pathogenesis [40] and 359 
higher circulating OPG concentrations have been reported in AA patients and positively 360 
associated with AA progression [41, 42]. OPG promotes an inflammatory phenotype in aortic 361 
VSMCs through upregulation of cathepsin S (CTSS), MMP-2 and MMP-9 [43]. OPG 362 
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deficiency protects against AngII induced AA and aortic rupture [43]. We found that 363 
upregulation of SOST downregulated OPN and OPG within mouse aortas suggesting that 364 
inhibition of the Wnt pathway due to SOST protected from AA as a result of downregulating 365 
these pro-aneurysmal genes.  366 
 367 
AngII has been reported to play a crucial role in several vascular pathologies including AA 368 
and atherosclerosis [44, 45]. AngII infusion is reported to promote aneurysm formation in 369 
both the thoracic and abdominal aorta in mice [19, 21, 46, 47]. Our animal model studies 370 
suggest that SOST inhibits AngII-induced AA in both the thoracic and abdominal aorta and 371 
also inhibits AngII-induced atherosclerosis.  372 
 373 
Consistent with previous findings [48, 49], AngII infusion for 28 days elevated the systemic 374 
levels of inflammatory cytokines in ApoE-/- mice. The levels of Th2 cytokines such as MCP-1, 375 
IL-6, 1L-10, TNF-α and IFN-γ were significantly decreased in SOSTTg.ApoE-/- mice and a 376 
similar but non-significant trend was observed in AngII infused ApoE-/- administered rmSost. 377 
The decrease in Th2 cytokines together with the reduction in macrophages within the aortic 378 
wall assessed by IHC, suggests that Wnt pathway suppression mediated by SOST limited 379 
both systemic and aortic wall inflammation. TGF-β1 has been reported to inhibit AngII-380 
induced AA and SOST has been linked with TGF-β1 [50, 51]. Plasma concentrations of total 381 
and active TGF-β1 were similar in mice with and without SOST upregulation suggesting 382 
there was unlikely to be an important effect of SOST on TGF-β1 in the mouse models 383 
studied. 384 
 385 
Collagen limits vessel distension, while elastin contributes to arterial elasticity. During AA 386 
development, collagen and elastin gradually fragment and degrade, eventually leading to 387 
increased aortic stiffness and decreased strength [52, 53]. VSMCs are crucial structural 388 
support elements and are the major source of elastin and collagen. Under pathological 389 
conditions such as AA, VSMCs undergoes phenotypic switching and release MMPs which 390 
results in ECM degradation. Dysfunction and depletion of VSMCs directly promotes AA. We 391 
found that SOSTTg.ApoE-/- and ApoE-/- mice receiving rmSost showed well-preserved aortic 392 
architecture with intact elastin fibers and collagen after 28 days of AngII infusion. Previous 393 
reports suggest that activation of canonical Wnt pathway stimulates fibrosis in vivo and in 394 
vitro [54]. Furthermore, previous in vitro observations in primary chondrocytes and mouse 395 
dermal fibroblasts suggest that SOST mediated Wnt/β-catenin pathway inhibition is crucial in 396 
regulating expressions of various ECM regulating genes and thereby preserving the aorta 397 
structure [55, 56].  398 
 399 
We report that SOST is downregulated and the Wnt/β-catenin signalling pathway activated 400 
in AA. Our observation is supported by a recent microarray study which reported that Wnt/β-401 
catenin signalling and several Wnt/β-catenin pathway target genes were upregulated in the 402 
arterial intima and media during aging, which is an important risk factor for AA and 403 
atherosclerosis [57]. Studies also suggest that canonical Wnt signalling promotes 404 
mammalian aging and aging-related phenotypes [58, 59] suggesting a mechanistic link 405 
between Wnt signalling and cardiovascular disorders in the elderly [11]. In addition, inhibition 406 
of Gsk-3β by lithium has been shown to activate Wnt pathway and promote endothelial cell 407 
senescence [60]. It is also evident from previous reports that during arterial aging, VSMCs 408 
switch from a proliferative response to non-proliferative response following Wnt/β-catenin 409 
activation [57]. It is also noteworthy that the proliferative response to β-catenin activation is 410 
abolished in VSMCs from old animals as well as in vitro aged VSMCs [57]. This suggests 411 
that VSMCs in the vessels of elderly subjects may not proliferate efficiently in response to β-412 
catenin activation favouring AA formation [61]. This could explain to some extent the role of 413 
SOST in AA, where downregulation of SOST might promote the senescent phenotypes of 414 
arterial cells. 415 
 416 
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A number of factors such as aging and risk factors such as smoking may promote epigenetic 417 
silencing of genes in AA [1, 62-64]. Several lines of evidences suggest an important role of 418 
altered epigenetic status in inflammation, proliferation and remodelling processes which are 419 
also associated with the development of AA, indicating that epigenetic changes may play an 420 
important role in AA pathogenesis [1] (Figure 6 D). Covalent addition of methyl groups at the 421 
5’ position of cytosines within CpG nucleotides in the gene promoter is a major mechanism 422 
of epigenetic regulation and silencing of transcription [65, 66]. We assessed the DNA 423 
methylation levels in AA tissues compared to controls, showing for the first time that SOST 424 
promoter is hyper-methylated in AA. Our study is supported by previous studies showing that 425 
the CpG island in the SOST promoter region is regulated by DNA methylation [31, 67] and 426 
plays an important role in the transcriptional regulation of the SOST gene [68]. Recent in 427 
vitro studies reported that methylation of CpG sites impaired nuclear binding protein and 428 
lead to ~75% inhibition of SOST promoter activity in human osteocyte cells [31, 67].  429 
 430 
Intraluminal thrombus has been suggested as important in AA pathogenesis [69, 70]. Our in 431 
vitro studies showed that incubation of VSMCs with AA-thrombus conditioned media led to 432 
down regulation of SOST mRNA expression and upregulation of CTNNB1 mRNA 433 
expression. Incubation of VSMCs with 5-Aza resulted in the upregulation of SOST 434 
expression and concomitant downregulation of CTNNB1, suggesting that epigenetic 435 
regulation of SOST might be involved in the regulation of Wnt pathway target gene 436 
expression. In vitro demethylation by 5-Aza resulted in a ~3 fold increase in SOST mRNA 437 
expression in the human aortic VSMCs. This observation is similar to a previous report of 438 
human osteoblastic cell MG-63 [67]. Our observation in AA biopsies and in vitro data 439 
together suggest that epigenetic downregulation of SOST is an important event in AA 440 
pathogenesis.  441 
 442 
It is currently thought that the methylation pattern is stably maintained in fully differentiated 443 
cells; however, compared with other epigenetic modifications, DNA methylation patterns can 444 
change in adult cells leading to altered gene expression and also potentially contributing to 445 
many diseases [1, 63, 71-73]. Recently, cigarette smoking was shown to activate polycomb 446 
machinery to repress a Wnt signalling antagonist DKK-1 in lung cancer cells, suggesting that 447 
additional genes in the Wnt pathway may be epigenetically silenced in AA [74]. Epigenetic 448 
processes are potentially reversible and a number of epigenetic drugs are currently being 449 
evaluated for the treatment of various diseases [1]. It may also be possible to safely 450 
modulate the epigenetic machinery by exogenous factors such as improved nutrition and 451 
positive life style modification [1, 63, 75].  452 
 453 
This study has several strengths and limitations. The research incorporated two mouse 454 
models, in vitro and human tissue studies which all suggested that SOST may be important 455 
in limiting AA and atherosclerosis. However the effects of rmSost injection were less marked 456 
than that of transgenic upregulation of SOST, most likely because the degree of upregulation 457 
achieved was less marked and transient. However, we did not measure the levels of 458 
circulating rmSost. Another limitation of this study is that we did not have corresponding 459 
mRNA to assess the relative SOST gene expression in the human control and AA tissues in 460 
which DNA methylation was assessed. Ideally the tissues obtained from the same patient 461 
should be analysed for DNA methylation pattern and the specific mRNA abundance but this 462 
was not possible.  463 
 464 
Our findings suggest that SOST upregulation could be a potential means to inhibit AA and 465 
atherosclerosis in patients. It should be noted though that exogenous SOST administration 466 
could promote osteoporosis. In fact SOST blocking treatments are being investigated for the 467 
treatment of osteoporosis [76, 77]. It is possible that such treatments will promote AA and 468 
atherosclerosis and thus patients should be carefully monitored for these complications [78].  469 
 470 
Conclusion 471 
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 472 
The present study, shows for the first time that epigenetic inactivation of SOST appears to 473 
be present in human AA. Our study provides new insights into the role of SOST in the 474 
pathogenesis of AA and atherosclerosis. We show here that SOST plays a protective role in 475 
maintaining aortic homeostasis by several mechanisms such as inhibiting inflammation and 476 
ECM degradation. In conclusion, this study provides evidence that loss of SOST activates 477 
Wnt/ β-catenin signalling, which regulates downstream genes important in maintaining aortic 478 
wall integrity. The findings have important implications for on-going trials of treatments to 479 
interfere with SOST in patients with osteoporosis. 480 
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Highlights 730 
• Sclerostin is an important controller of bone mineralisation. 731 
• Sclerostin is expressed in the human and mouse aorta but downregulated in aortic 732 
aneurysm. 733 
• Sclerostin protects against angiotensin II-induced aortic aneurysm and 734 
atherosclerosis in mouse models most likely as a resulted of its ability to inhibit the 735 
wingless pathway.  736 
• The sclerostin gene appears to be epigenetic silenced in human aortic aneurysm 737 
samples. 738 
 739 
 740 
  741 
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Table 1. Concentrations of pro-inflammatory cytokines (pg/ml) in the platelet poor plasma of 742 
AngII-infused control ApoE-/- mice, SOSTTg.ApoE-/- and ApoE-/- mice administered rmSost for 743 
28 days. 744 
 745 
Sl. No. Sample ApoE-/-   SOST
Tg.ApoE-
/- 
P 
value 
ApoE-/-  
rmSost   
P 
value 
1 
Monocyte 
Chemoattractant 
Protein-1 (MCP-1) 
145.50 ± 
48.51 31.49 ± 14.23 0.003 62.34 ± 8.58 0.237 
2 Interleukin-6 (IL-6) 33.98 ± 12.75 1.78 ± 1.39 0.010 15.99 ± 5.64 0.993 
3 Tumor Necrosis Factor (TNF)-α 
43.83 ± 
25.00 9.71 ± 0.92 0.041 13.77 ± 1.82 0.910 
4 Interleukin-10 (IL-10) 
50.32 ± 
40.90 3.46 ± 2.38 0.079 7.63 ± 3.03 0.669 
5 Interferon (IFN)-γ 7.61 ± 6.30 0.36 ± 0.22 0.092 1.10 ± 0.33 0.910 
6 Interleukin-12p70 (IL-12p70) 
107.90  
±85.09 4.44 ± 3.61 0.060 21.00 ± 5.59 0.833 
7 TGF-β1 (Total) 41.66 ± 8.90 57.24 ± 9.76 0.450 58.32 ± 9.75 0.275 
8 TGF-β1 (Active) 0.16 ± 0.04 0.17 ± 0.45 0.920 0.14 ± 0.03 0.679 
 746 
All groups received subcutaneous infusion of Angiotensin II for 28 days. Data presented as 747 
mean ± standard error of mean (S.E.M). Results were compared to the control ApoE-/- by the 748 
Kruskal-Wallis test with Dunn's post-hoc correction. Abbreviations: ApoE-/-, apolipoprotein E 749 
deficient; rmSost, recombinant mouse Sclerostin protein; SOSTTg, sclerostin transgenic; 750 
TGF-β1, transforming growth factor beta 1. 751 
 752 
 753 
 754 
  755 
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Table 2. Relative gene expressions in the SRAs of AngII-infused control ApoE-/-, AngII- 756 
SOSTTg.ApoE-/- and ApoE-/- mice administered with rmSost for 28 days. 757 
 758 
Sl. 
No. Gene Sample N Median (IQR) P value 
1 Mmp9 ApoE-/-  6 5.65 (4.08-8.68)  
  SOST
Tg.ApoE-/- 6 1.35 (0.93-2.77) 0.002 
    ApoE-/- + rmSost  6 1.30 (0.44-3.61) 0.041 
2 Spp1 ApoE-/-  6 2.55 (1.57-4.59)  
  SOST
Tg.ApoE-/- 6 0.94 (0.38-1.49) 0.030 
    ApoE-/- + rmSost  6 0.72 (0.14-1.95) 0.041 
3 Tnfrsf11b ApoE-/-  6 4.67 (1.82-5.86)  
  SOST
Tg.ApoE-/- 6 0.40 (0.18-3.17) 0.030  
    ApoE-/- + rmSost  6 2.79 (1.95-3.91) 0.420 
4 Ctnnb1 ApoE-/-  6 20.50 (8.90-39.69)  
  SOST
Tg.ApoE-/- 6 7.17 (3.90-10.92) 0.035  
    ApoE-/- + rmSost  6 9.39 (1.21-15.33) 0.073 
 759 
 760 
All groups received subcutaneous infusion of Angiotensin II for 28 days. Data expressed as 761 
median (interquartile range). Results were compared to the control ApoE-/- by the Kruskal-762 
Wallis test with Dunn's post-hoc correction and expressed as relative expression of gene 763 
compared to glyceraldehyde 3-phosphate dehydrogenase (Gapdh). Abbreviations: 764 
Abbreviations: ApoE-/-, apolipoprotein E deficient; Ctnnb1, β-Catenin; IQR, inter-quartile 765 
range; Mmp, matrix metalloproteinase; n, sample number; Tnfrsf11b, osteoprotegrin; Spp1, 766 
osteopondin; rmSost, recombinant mouse Sclerostin protein; SOSTTg, sclerostin transgenic. 767 
 768 
 769 
 770 
 771 
 772 
 773 
 774 
 775 
 776 
 777 
 778 
 779 
 780 
 781 
 782 
 783 
 784 
 785 
 786 
 787 
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Figure Legends 788 
 789 
Figure 1. SOST was downregulated within AngII-induced AAs of ApoE-/- mice.  790 
A (i) Western blot showing expression of SOST within SRA samples from mice that 791 
developed (n=5) and did not develop (n=6) AA after 28 days of AngII infusion. Relative SRA 792 
SOST expression was ~3-fold downregulation in mice that developed AngII induced AA 793 
compared to mice that did not develop AngII–induced AA. (ii) Immunoblots were quantified 794 
and analysed by densitometry, and the ratio of SOST protein was normalized to β-actin and 795 
shown as relative levels (AU, arbitrary units). Data presented as median and interquartile 796 
ranges (whiskers). B. (i) Immunoblot for SOST protein expression in SRA segments from 797 
ApoE-/- (n=5) and SOSTTg.ApoE-/- mice (n=5). An increased expression of SOST protein was 798 
observed in the SRA extracts from SOSTTg.ApoE-/- mice (AU, arbitrary units). (ii) 799 
Quantification of median SOST protein expression relative to GAPDH. Immunoblots were 800 
quantified and analysed by densitometry, and the ratio of SOST was normalized to GAPDH. 801 
Data presented as median and interquartile ranges (whiskers). Abbreviations: AA, aortic 802 
aneurysm; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; SOST, sclerostin; SRA: 803 
supra-renal aorta. 804 
 805 
Figure 2. SOST upregulation protected ApoE-/- mice from AngII-induced AA.  806 
A. (i) Representative images of aortas from ApoE-/- (n=12) and SOSTTg.ApoE-/-mice (n=12) 807 
infused with AngII for 28 days. Regional maximum diameters of SOSTTg.ApoE-/- mice were 808 
determined by ex vivo morphometric measurements at the end of the AngII infusion. (ii) Ex 809 
vivo measurement of aortic arch, thoracic, suprarenal and infrarenal aortic regions showed 810 
that AngII-infused SOSTTg.ApoE-/- mice had a significantly smaller diameters compare to 811 
AngII-infused ApoE-/- mice. Quantification graph showing median and interquartile ranges 812 
(whiskers). B. (i) Representative images of AngII-induced AA in ApoE-/- mice administered 813 
with daily injection of recombinant mouse SOST (rmSost) protein (n=20) and ApoE-/- mice 814 
receiving vehicle control (n=20). Regional maximum aortic diameters were determined by ex 815 
vivo morphometric measurements at the end of 28 days of AngII infusion. (ii) Ex vivo 816 
measurement of aortic arch, thoracic, suprarenal and infrarenal aortic regions showed that 817 
mice receiving daily injection of rmSost had smaller aortic diameters than vehicle control 818 
mice. Quantification graph showing median and interquartile ranges (whiskers). C. Aortic 819 
arch Sudan IV staining areas for quantifying atherosclerosis. Aortic arch Sudan IV staining 820 
areas in SOSTTg.ApoE-/- mice and mice receiving rmSost were significantly smaller than the 821 
control ApoE-/- after 28 days of AngII infusion (n=6/group). Data presented as median and 822 
interquartile ranges (whiskers). Abbreviations: IRA, infrarenal aorta; SRA, suprarenal aorta; 823 
TA, thoracic aorta.  824 
 825 
Figure 3. SOST upregulation protected AngII-infused ApoE-/- mice from matrix 826 
degradation.  827 
A. Representative Hematoxylin and eosin (H&E) stained section of supra-renal aortic 828 
sections of (i) control ApoE-/- mice receiving AngII (ii) SOSTTg.ApoE-/- receiving AngII and (iii) 829 
ApoE-/- receiving AngII and rmSost. Representative high power images of (i) AngII-infused 830 
control ApoE-/- mice showed a marked increase in inflammatory cell infiltrates and matrix 831 
degradation compared to (ii) SOSTTg.ApoE-/- receiving AngII or (iii) ApoE-/- receiving AngII 832 
and rmSost. Scale bar: 50µm (* Lumen). B. Comparison of medial elastin filament breaks 833 
(black structures) within Verhoeff-Van Giesson (EVG) stained sections of suprarenal aortas. 834 
The control ApoE-/- mice receiving AngII (i) showed higher grade elastin filament breakdown 835 
compared to (ii) SOSTTg.ApoE-/- receiving AngII and (iii) ApoE-/- receiving AngII and rmSost. 836 
Scale bar: 50µm (* Lumen). C. Polarisation microscopy images of picrosirius red staining for 837 
collagen content within the suprarenal aorta. (i) Compared to the control ApoE-/- mice 838 
receiving AngII, (ii) SOSTTg.ApoE-/- receiving AngII and (iii) ApoE-/- receiving AngII and 839 
rmSost, showed increased collagen birefringence under polarisation. Scale bar: 10µm (* 840 
Lumen). D. Quantification graph showing elastin filament degradation (n=6 aorta/group). 841 
Aortic wall elastin filament degradation was graded based on the degree of breaks in elastin 842 
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filaments (graded on a scale of 1-4) as described in the materials and methods. E. 843 
Quantification of polarisation images for collagen content expressed as a percentage (%) of 844 
the total suprarenal aorta section area (n=6 aorta/group). Data shown as median and 845 
interquartile ranges. Abbreviations: AngII, angiotensin II; NS, not significant; rmSost, 846 
recombinant mouse sclerostin protein. 847 
 848 
Figure 4. SOST upregulation was associated with concomitant reduction of 849 
inflammatory cell infiltration and Wnt/β-catenin signalling pathway activation within 850 
the SRA of AngII infused ApoE-/- mice.  851 
A. Representative immunohistochemical low power (i, ii, iii) and high power micrographs (iv, 852 
v, vi) showing staining of macrophages using monocyte and macrophage antibody-2 853 
(MOMA-2) in AngII infused (I, iv) control ApoE-/- mice, (ii, v) SOSTTg.ApoE-/-, and (iii, vi) 854 
ApoE-/- mice receiving rmSost. Scale bar: 10µm (* Lumen). B. Quantification of macrophage 855 
infiltration (n=6 aorta/group). Six harvested SRA were randomly selected from each group 856 
for immunohistochemical staining for macrophages (MOMA-2). Staining area was estimated 857 
by computer-aided analysis. Shown are box plots representing median and interquartile 858 
ranges of staining areas from SRAs of each group. The staining areas for macrophages 859 
were reduced in SOSTTg.ApoE-/- and ApoE-/- mice receiving rmSost compared to controls 860 
receiving AngII alone. Data presented as median and interquartile ranges (whiskers). C. (i) 861 
Immunoblot showing a higher phosphor-GSK-3β : total GSK-3β ratio in the SRA samples 862 
from mice that developed AA (n=4) compared to the mice that did not develop AA (n=6) 863 
following 28 days of AngII infusion, suggesting that Wnt signalling is activated in AA. (ii) 864 
Quantification graph showing ~2 fold higher phosphor-GSK-3β : total GSK-3β ratio in the 865 
SRA samples from mice that developed (n= 4) and did not develop (n=6) AA following 28 866 
days of AngII infusion (P= 0.009). D. (i) Immunoblot showing aortic phosphor-GSK-3β : total 867 
GSK-3β ratio was lower in SOSTTg.ApoE-/- receiving AngII compared to control ApoE-/- mice 868 
receiving AngII alone. (ii) Quantification graph showing that aortic phosphor-GSK-3β : total 869 
GSK-3β ratio was significantly lower in AngII infused SOSTTg.ApoE-/- when compared to 870 
control ApoE-/- mice receiving AngII alone (n=6/group, P= 0.041). E. (i) Immunoblot showing 871 
that reduction of aortic GSK-3β activity in SOSTTg.ApoE-/- mice after 28 days of AngII infusion 872 
was not associated with changes in Akt signalling. Western blotting revealed no significant 873 
difference in aortic Akt activity (AU, arbitrary units). (ii) Quantification graph showing that 874 
aortic Akt activity (expressed as phosopho-Akt : total Akt ratio) was not significantly different 875 
between Ang-II infused SOSTTg.ApoE-/- and Ang-II infused control ApoE-/- mice (n= 5/group; 876 
P=0.412). Data presented as median and interquartile ranges (whiskers). Abbreviations: AA, 877 
aortic aneurysm; AngII, angiotensin II; NS, not significant; rmSost, recombinant mouse 878 
sclerostin protein; SRA, supra renal aorta.  879 
 880 
Figure 5. Aortic SOST protein level was downregulated in human AA.  881 
A. (i) Immunoblot showing median relative levels (AU, arbitrary units) of SOST protein 882 
expression (relative to β-actin expression) to be significantly lower in the AA samples (n=6) 883 
compared to the control biopsies (n=6). (ii) Blots were quantified and analysed by 884 
densitometry, and the ratio of SOST was normalized to β-actin. Quantification graph shows 885 
data presented as median and interquartile ranges (whiskers). B. Representative low power 886 
(×100) photomicrographs of immunohistochemical staining of SOST protein in cryostat 887 
sections obtained from biopsy samples of (i) relatively normal AA neck and (ii) diseased AA 888 
body. The section from the AA neck biopsy illustrates a relatively well maintained elastic 889 
media with minimal infiltration of the adventitia by inflammatory cells. Intense SOST protein 890 
staining is observed in the medial region with mild staining in the adventitial region. In 891 
contrast the biopsy from the body of the AA has marked medial elastin degradation and 892 
infiltration of the adventitia by inflammatory cells with minimal staining for SOST protein. 893 
Scale bar 50 µm. C. Expression of the CTNNB1 within AA neck and AA body biopsies. 894 
Quantitation graph depicts increased expression of CTNNB1 within AA body biopsies 895 
compared to AA neck biopsies (n=8/group, P=0.049 calculated with non-parametric Mann-896 
Whitney test). Data expressed as median and interquartile range with maximum and 897 
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minimum data points (whiskers) for relative gene expression. Abbreviations: AA, aortic 898 
aneurysm; CLT, control; CTNNB1, β-catenin gene; SOST, sclerostin gene.  899 
 900 
Figure 6. SOST was silenced in human AA by DNA methylation.  901 
A. (i) Schematic diagram of the human SOST gene promoter showing the relative position of 902 
transcription initiation site (TIS), CpG island and individual CpGs. (ii) The lower panel shows 903 
the enlarged detailed position of CpGs showing the status of DNA methylation. The filled 904 
lollipops show the relative position of CpGs and the empty positions show the CpGs that 905 
were not analysed. (iii) An example of the average percentage of DNA methylation observed 906 
in ten representative samples is given. Orange coloured circles represent no methylation, 907 
yellow coloured circles indicate 100% methylation and dotted clear circles represent CpGs 908 
not analysed. B. Bisulfite epityping showed the SOST promoter region to be significantly 909 
methylated in DNA from AAA body (n=32) compared to DNA from control aortic biopsies of 910 
organ donors (n=32). Data presented as mean + S.E.M. and analysed by t-test. Statistical 911 
significance was shown as P<0.0001. C. Wnt target genes were reactivated by epigenetic 912 
drugs in vascular smooth muscle cells (VSMCs). Quantitative RT-PCR of VSMCs incubated 913 
with vehicle controls, conditioned media or 5-Aza deoxycytidine (5-Aza). RNA was extracted 914 
from VSMCs incubated with vehicle or AA-thrombus conditioned media for 24 h after which 915 
5-Aza was added and cells incubated for an additional 24 h. RT-PCR analysis was carried 916 
out using gene specific primers. The graph shows gene expression of (i) SOST and (ii) 917 
CTNNB1, relative to GAPDH expression. (n=6/group). Abbreviations: AA, aortic aneurysm; 918 
CLT, control; CpG, cytosine-phosphate-guanine; CTNNB1, β-catenin gene; SOST, sclerostin 919 
gene. D. Working model of SOST action in AA pathogenesis. Epigenetic alteration leads to 920 
the silencing of SOST gene. When active, SOST binds to Wnt co-receptor LRP5/6 to inhibit 921 
Wnt1 class signalling. Wnt interacts at the cell surface with frizzled receptor (Fzd) and low-922 
density lipoprotein receptor-related 5/6 (LRP5/6). In the cytoplasm, β-catenin binds to the 923 
multiprotein complex containing kinases such as Gsk3-β Casein kinase-1, which 924 
phosphorylates specific amino acids on the β-catenin. In the absence of Wnt, β-catenin is in 925 
a steady state and free β-catenin is eventually degraded by 26S proteasome. Activation of 926 
Wnt signalling releases the β-catenin from the binding proteins, inhibits its phosphorylation, 927 
increases the cytoplasmic levels and eventually promotes its nuclear translocation. After the 928 
nuclear translocation, β-catenin interacts with transcriptional factors initiating the expression 929 
of several target genes. When SOST promoter undergoes inactivation due to DNA 930 
methylation, it results in the activation of Wnt signalling promoting atherosclerosis, 931 
inflammation and ECM degradation promoting AA formation. (Red arrows show activated 932 
pathway and blue shows inhibition). Abbreviations: AA, aortic aneurysm; ECM, extracellular 933 
matrix; P, phosphorylation; SOST, sclerostin; TF, transcription factor; Ub, ubiquitination.  934 
 935 
 936 
 937 
